Analyst Phil Nadeau of Cowen downgraded shares of Zafgen Inc (NASDAQ:ZFGN) from Outperform to Market Perform, after the biotech company terminated one of its pipeline drugs, …
Cowen analyst Ritu Baral‘s stance on eteplirsen, Sarepta Therapeutics Inc (NASDAQ:SRPT) pipeline drug for Duchenne Muscular Dystrophy, DMD, is unchanged. This comes after Santhera …
Analysts weigh in on biotechnology stocks Juno Therapeutics Inc (NASDAQ:JUNO) and Cempra Inc (NASDAQ:CEMP). Both are bullish as Juno Therapeutics receives $50 million from collaboration partner Celgene, …